Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
The purpose of this study is to evaluate the safety and efficacy of SCT-I10A combined SCT200 or SCT-I10A combined SCT200 plus chemotherapy in advanced esophageal squamous cell carcinoma and colorectal cancer
Esophageal Squamous Cell Carcinoma|Colorectal Cancer
BIOLOGICAL: SCT-I10A|BIOLOGICAL: SCT200|OTHER: Chemotherapy
Rate of adverse events, Including adverse events and safety of laboratory tests, 24 months
Objective response rate (ORR), ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 or Lugano 2014 criteria during trial treatment, 24 months|Duration of response (DOR), DOR is defined as time from the date when a patient first meets the criteria for CR or PR according to RECIST v1.1 or Lugano 2014 criteria, until the date that progressive disease (PD) is objectively documented or death, whichever occurs first, 24 months|Disease control rate (DCR), The achievement of any a stable response（SD）, partial response (PR) or complete response (CR), according to RECIST v1.1 or Lugano 2014 criteria, 24 months|Progression free survival (PFS), PFS is defined as the time from first dose of SCT200 until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 or Lugano 2014 criteria, 24 months|Overall survival (OS), OS is defined as time from first dose of SCT200 until the date of death from any cause, 24 months
This is a open label, multicenter, phase III study designed to evaluate the safety and efficacy in advanced esophageal squamous cell carcinoma and colorectal cancer treated with SCT-I10A combined SCT200 or SCT-I10A combined SCT200 plus chemotherapy.